Nachrichten zur Johnson Service Group PLC Aktie

Johnson & Johnson Aktie: Pharma-Boom federt Medtech-Schwäche ab

Frankfurt (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von XTB:Die Aktie von Johnson & Johnson (J&J) (ISIN: US4781601046, WKN: 853260, Ticker-Symbol: JNJ,…

Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Bristol-Myers trades at a significant valuation discount, but its higher leverage and patent risks contrast sharply with Johnson & Johnsons…

Johnson & Johnson: 3 Key Takeaways for Long-Term Investors

MedTech growth stalled while pharma surged, leaving the company to bet on new product launches and a planned spin-off to…

Johnson & Johnson: 3 Key Takeaways for Long-Term Investors

MedTech growth stalled while pharma surged, leaving the company to bet on new product launches and a planned spin-off to…

Johnson & Johnson Aktie: Starkes drittes Quartal - doch 2027 droht Stagnation

New York (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Bernstein:Die Analysten von Bernstein heben ihr Kursziel für die Aktie von Johnson…

JNJ Q3 Earnings Call Highlights Growth Outlook and MedTech Challenges

Johnson & Johnson raises its 2026 sales and earnings outlook as strong pharmaceutical growth offsets MedTech challenges, while 2027 dilution…

Johnson & Johnson: Keep Calm And Hold On

…

Johnson & Johnson (JNJ) Q3 2026 Earnings Call Transcript

…

Stock Market Midday, Oct. 13: Bank Earnings and Chip Pressure Drive Mixed Trading

Goldman Sachs gains on strong revenue while Johnson & Johnson stumbles on earnings miss, today, Oct. 13, 2026.…

Johnson & Johnson beats estimates, raises 2026 guidance

Johnson & Johnson beats estimates, raises 2026 guidance…

Johnson & Johnson raises 2026 guidance as quarterly sales climb

Johnson & Johnson (NYSE:JNJ), the healthcare group, raised its 2026 sales and earnings forecasts after third-quarter sales grew 6% on…

MARKETS LIVE: US stocks trade mixed as chipmakers weigh on markets

11:35am: J&J, Dominos report Big banks werent the only sector reporting results on Tuesday. Johnson & Johnson (NYSE:JNJ) (Johnson &…

UnitedHealth vs. Johnson & Johnson: Which Stock Is the Better Buy After Q3 Earnings?

Healthcare giants UnitedHealth Group and Johnson & Johnson reported Q3 results on Tuesday, with both raising their full-year earnings outlooks…

Deutsche Bank trims Johnson Service Group target to 200p on weak catering demand and rising energy costs

Deutsche Bank cut its price target on Johnson Service Group plc (LSE:JSG) to 200p from 210p, citing weaker trading among…

Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?

Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key…

Johnson & Johnson (JNJ) Earnings Expected to Grow: Should You Buy?

Johnson & Johnson (JNJ) doesnt possess the right combination of the two key ingredients for a likely earnings beat in…

Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026?

JNJ trades at a 28% discount on valuation while LLYs cardiometabolic drugs drive 82% of revenue, each bet carries distinct…

Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale

Johnson & Johnsons revenue base runs roughly double Bristol-Myers Squibbs, with the gap showing signs of widening over the past…

Jabil’s Double-Beat and Raise Is a Signal That This Rally Will Continue

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.…

3 Reasons Johnson & Johnson Is Still a Buy With Its Stock Near a Record High

This is not an exhaustive list.…

Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy…

AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie bets on pipeline diversification amid patent cliffs, while J&Js higher profitability masks litigation risks, a choice between growth ambition…

Johnson & Johnson says Tremfya eases spinal pain in Phase 4 psoriatic arthritis study

Johnson & Johnson (NYSE:JNJ) said its Tremfya treatment significantly improved spinal pain and stiffness in adults with axial psoriatic arthritis…

Johnson & Johnson May Offload Its Orthopedics Unit for $20 Billion -- and Investors Shouldnt Miss What That Could Signal

Healthcare giant Johnson & Johnson is looking to become a more profitable and faster-growing business.…

Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight

The launch of emerging therapies such as ILUMYA/ILUMETRI (tildrakizumab-asmn; Sun Pharma), Izokibep (Affibody Medical), ICOTYDE (icotrokinra; Johnson & Johnson), Zasocitinib…

Johnson & Johnson (JNJ) Presents at Deutsche Bank 2026 Healthcare Summit Transcript

…

Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy…

3 Top Dividend Aristocrats To Own Near All-Time Highs

Several Dividend Aristocrats, including Johnson & Johnson (JNJ), Coca-Cola (KO), and Exxon Mobil (XOM), are trading near all-time highs, reflecting…

Johnson & Johnson Aktie: Warum HSBC trotz hoher Bewertungen zum Kauf rät

London (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von HSBC:HSBC habe das Kursziel für die Aktie von Johnson & Johnson (J&J) (ISIN:…

Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Johnson & Johnson (JNJ) reached $269.12 at the closing of the latest trading day, reflecting a -2.22% change compared to…

J&Js run to record highs hasnt reached the finish line yet. Here are the key drivers

Jim Cramer agrees with UBS: The rally in Johnson & Johnson shares still has room to run.…

Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts

Johnson & Johnson (JNJ) closed at $271.19 in the latest trading session, marking a +2.01% move from the prior day.…

AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.…

Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy…

Warren Buffett Thinks Investors Are "Gambling" Right Now. Here are 2 Stocks That Should Be Safe Bets.

Johnson & Johnson and Merck are healthcare giants with dependable returns that weather economic downturns well.…

Johnson & Johnson Just Got a Big FDA Win

The companys autoimmune drug was approved for the treatment of a rare blood disease.…

The Zacks Analyst Blog Highlights JPMorgan, Johnson & Johnson, Mastercard and Comstock

JPMorgan leads today???s featured research, with growth drivers, strategic moves and key risks highlighted across major stocks and a microcap.…

Top Analyst Reports for JPMorgan, Johnson & Johnson & Mastercard

JPMorgan, Johnson & Johnson and Mastercard headline todays research, with growth drivers and key risks shaping each stocks outlook.…

Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know

In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $270.27, denoting a -1.05% move from…

Q2 Earnings Season Winds Down: 3 Companies That Broke Records

The 2026 Q2 earnings cycle continues to wind down, with the reporting docket starting to get quiet. The period has…

Better Dividend King to Buy Right Now: Abbott Labs or Johnson & Johnson?

These two high-quality dividend payers have had very different fortunes recently.…

Johnson & Johnson: Buy IMAAVY Label Expansion First And Continued CAPLYTA Sales Push

…

ACHV: Looking Ahead to Resubmission

By John Vandermosten, CFANASDAQ: ACHVREAD THE FULL ACHV RESEARCH REPORTAchieve Life Sciences, Inc. (NASDAQ: ACHV) reported second quarter results, introducing…

Why Is Johnson & Johnson (JNJ) Up 4.8% Since Last Earnings Report?

Johnson & Johnson (JNJ) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings…

This Dividend Aristocrat Posted Record Quarterly Results

Johnson & Johnson shares have quietly delivered a huge gain in 2026 so far, up more than 25%. The gain…

Jim Cramer Analyzes Johnson & Johnson (JNJ) After Surgical Robotics Milestone

Jim Cramer celebrated a dramatic pivot in market sentiment surrounding Johnson & Johnson (NYSE:JNJ) during Mad Money’s July 23 episode.…

Explainer: Can J&J finally put the talc litigation behind it?

After years of failed attempts to resolve thousands of lawsuits alleging that its talc products caused cancer, Johnson & Johnson…

Johnson & Johnson vs. Eli Lilly: Reliable Stability vs. Rapid Revenue Growth

Johnson & Johnsons revenue has grown modestly while Eli Lillys revenue has nearly doubled in two years, narrowing a once-wide…

J&J-Aktie gefragt: Johnson & Johnson will Talkum-Klagen mit milliardenschwerem Vergleich beilegen

Der US-Pharmakonzern will 5,5 Milliarden US-Dollar zur Beilegung der Klagen bereitstellen. Johnson & Johnson hatte bereits tags zuvor die Konditionen…

Rechtsstreit endet mit Vergleich: Krebserregendes Babypuder? US-Firma zahlt Milliarden

Etliche Klägerinnen werfen Johnson & Johnson vor, durch die Verwendung seiner talkumbasierten Babypuder-Produkte an Eierstockkrebs erkrankt zu sein. Der US-Pharmakonzern…